A Single-Dose, Double-Blind, Placebo-Controlled, Randomized, Crossover Study to Determine the Abuse Potential of Single Oral Dose of Seltorexant Compared To Suvorexant and Zolpidem
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Seltorexant (Primary) ; Zolpidem (Primary)
- Indications Insomnia; Major depressive disorder; Sleep apnoea syndrome
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 20 Jul 2023 Status changed from recruiting to completed.
- 20 Apr 2023 Planned number of patients changed from 200 to 150.
- 20 Apr 2023 Planned End Date changed from 6 Mar 2023 to 15 Jun 2023.